Accanito Therapeutics is a clinical‑stage oncology company developing first‑in‑class, mitochondria‑targeted therapies designed to address multiple tumor types.Our lead asset inhibits HSP within tumor mitochondria, triggering irreversible mitochondrial collapse and selective cancer cell death. This differentiated mechanism of action positions our platform to address significant unmet needs across solid and hematologic tumors.Headquartered in Bay Area, Accanito is led by an international team of biotech entrepreneurs and seasoned pharmaceutical executives committed to advancing transformative cancer treatments.
